On April 25, Ganli Pharmaceutical, a leading insulin company, released its first quarter report for 2025, reporting an excellent performance with both revenue and net profit growing. According to the report, the company's Q1 operating income reached 985 million yuan, a year-on-year increase of 75.76%; net profit attributable to shareholders of listed companies reached 312 million yuan, a year-on-year increase of 224.9%; net profit attributable to shareholders after deducting non-recurring items reached 215 million yuan, a year-on-year increase of 1150.2%.

From the perspective of revenue structure, Gan & Lee Pharmaceuticals achieved significant growth in both domestic and overseas revenue, which jointly drove the increase in overall revenue.

In the domestic market, Ganli Pharmaceuticals performed strongly, with sales revenue reaching 889 million yuan, an increase of 395 million yuan over the same period last year, a year-on-year increase of 80.07%. This is mainly due to the substantial increase in sales of its insulin preparations. In 2024, the company actively participated in the national insulin special follow-up centralized procurement bidding and achieved positive results. The new centralized procurement cycle will last from May 2024 to December 2027. With the dividends of the implementation of the centralized procurement results, the company's domestic insulin preparation product sales revenue reached 864 million yuan in the first quarter of 2025, a year-on-year increase of 80.93%. Among them, the sales revenue of basal (long-acting) insulin products was 543 million yuan, a year-on-year increase of 80.97%; the sales revenue of mealtime (rapid-acting) and premixed insulin products was 321 million yuan, a year-on-year increase of 80.86%. The sales volume and price growth effects appeared synergistically, contributing 238 million yuan and 148 million yuan to revenue growth respectively.

In the international market, Gan & Lee Pharmaceuticals also made significant progress, with international sales revenue of RMB 95 million, a year-on-year increase of 45.21%. The company insists on using innovation to drive the development of its export business, continuously improving the international competitiveness of its core products, and steadily expanding its international market, providing strong support for revenue growth.

In the first quarter of 2025, Ganli Pharmaceutical achieved a net profit attributable to shareholders of RMB 312 million, a year-on-year increase of 224.9%; the non-recurring net profit attributable to shareholders of the parent was RMB 215 million, a year-on-year increase of 1150.2%. On the one hand, this is due to the substantial growth in operating income, which laid the foundation for profit growth; on the other hand, the company has also achieved remarkable results in cost control and improving operational efficiency. During the reporting period, Ganli Pharmaceutical's gross profit margin was as high as 76.76%, demonstrating the company's strong profitability.

In addition, the company's net operating cash flow also performed well, reaching 159 million yuan, a year-on-year increase of 95.3%, which shows that the company's operating activities generated sufficient cash flow, providing strong financial support for the company's continued development and expansion.

In terms of R&D expenses, Ganli Pharmaceutical's R&D expenses in the first quarter of 2025 decreased slightly, but still maintained at a high level of 130 million yuan, accounting for 13.2% of operating income. The company has long attached great importance to R&D investment and continuously launched innovative products and technologies to meet the needs of the market and patients. Its products under development are rich, covering multiple therapeutic areas such as diabetes and tumors, laying a solid foundation for the company's long-term development. For example, the company's ultra-fast-acting insulin analog Lispro has completed Phase III clinical trials and applied for listing, and new products such as finger vein blood glucose meters are also in the R&D or registration stage, which will become the company's future growth points.

Conclusion: Gan & Lee Pharmaceuticals' revenue and net profit both increased in the first quarter of 2025, demonstrating its strong strength and competitive advantage in the field of diabetes treatment. Through a series of measures such as actively participating in centralized procurement, expanding domestic and foreign markets, and continuously increasing R&D investment, the company has achieved rapid growth in performance and laid a solid foundation for future development. With the support of broad market prospects, Gan & Lee Pharmaceuticals is expected to continue to maintain a good development momentum, provide patients with more high-quality diabetes treatment products and services, and also create greater value for investors.

https://news.yaozh.com/archive/45367.html